TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data

Human Mutation

Volumn 37, Issue 9, 2016, Pages 865-876

  Bouaoun, Liacine ^a   Sonkin, Dmitriy ^b   Ardin, Maude ^a   Hollstein, Monica ^a,c   Byrnes, Graham ^a   Zavadil, Jiri ^a   Olivier, Magali ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

annotations; cancer; germline variations; locus specific database; mutation hotspots; somatic mutations; TP53

Indexed keywords

PROTEIN P53;

ARTICLE; DATA BASE; DNA BINDING; GENE MUTATION; GENETIC VARIATION; GERMLINE MUTATION; HUMAN; NEOPLASM; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; SCISEARCH; SOMATIC MUTATION; TUMOR GENE;

EID: 84982193679     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.23035     Document Type: Article

References (37)

1. Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, Da Rocha JC, Vettore AL, et al. 2007. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 245:96–102.
2. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. 2010. A method and server for predicting damaging missense mutations. Nat Methods 7:248–249.
3. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603–607.
4. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM. 2001. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20:4621–4628.
5. Bressac B, Kew M, Wands J, Ozturk M. 1991. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429–431.
6. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. 2009. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37:e67.
7. Efeyan A, Ortega-Molina A, Velasco-Miguel S, Herranz D, Vassilev LT, Serrano M. 2007. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res 67:7350–7357.
8. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, et al. 2004. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80.
9. Hodges E, Xuan Z, Balija V, Kramer M, Molla MN, Smith SW, Middle CM, Rodesch MJ, Albert TJ, Hannon GJ, McCombie WR. 2007. Genome-wide in situ exon capture for selective resequencing. Nat Genet 39:1522–1527.
10. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. 1991. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427–428.
11. Hubbell E, Liu WM, Mei R. 2002. Robust estimators for expression analysis. Bioinformatics 18:1585–1592.
12. Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, Murakami M, Ruetz S, Guthy DA, Rynn C, Jensen MR, Wiesmann M, et al. 2015. A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. Elife 4.
13. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, et al. 2013. Mutational landscape and significance across 12 major cancer types. Nature 502:333–339.
14. Kumar P, Henikoff S, Ng PC. 2009. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081.
15. Lu X, Errington J, Curtin NJ, Lunec J, Newell DR. 2001. The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res 7:2114–2123.
16. Lunter G, Hein J. 2004. A nucleotide substitution model with nearest-neighbour interactions. Bioinformatics 20 Suppl 1:I216–I223.
17. Luo JL, Yang Q, Tong WM, Hergenhahn M, Wang ZQ, Hollstein M. 2001. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20:320–328.
18. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, et al. 2009. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4:e7887.
19. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238.
20. Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV. 2006. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 34:1317–1325.
21. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA. 2003. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63:6643–6650.
22. Olivier M, Hainaut P, Borresen-Dale AL. 2005. Prognostic and predictive value of​TP53 mutations in human cancer. In:Hainaut P, Wiman K, editors. 25 Years of p53 Research. Dordrecht, The Netherlands: Springer. p 320–328.
23. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622–629.
24. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. 2002. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking- associated cancers. Oncogene 21:7435–7451.
25. R Development Core Team. 2014. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
26. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, et al. 2001. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98:9330–9335.
27. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. 2011. Integrative genomics viewer. Nat Biotechnol 29:24–26.
28. Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J. 2013. A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Dis 4:e492.
29. Saiki AY, Caenepeel S, Cosgrove E, Su C, Boedigheimer M, Oliner JD. 2015. Identifying the determinants of response to MDM2 inhibition. Oncotarget 6:7701–7712.
30. Slebos RJ, Resnick MA, Taylor JA. 1998. Inactivation of the p53 tumor suppressor gene via a novel Alu rearrangement. Cancer Res 58:5333–5336.
31. Sonkin D. 2015. Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors. Elife 4.
32. Sonkin D, Hassan M, Murphy DJ, Tatarinova TV. 2013. Tumor suppressors status in cancer cell line Encyclopedia. Mol Oncol 7:791–798.
33. Wade M, Li YC, Wahl GM. 2013. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13:83–96.
34. Westwood G, Dibling BC, Cuthbert-Heavens D, Burchill SA. 2002. Basic fibroblast growth factor (bFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway. Oncogene 21:809–824.
35. Whibley C, Pharoah PD, Hollstein M. 2009. p53 polymorphisms: cancer implications. Nat Rev Cancer 9:95–107.
36. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, et al. 2013. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 41:D955–961.
37. Yu D, Berlin JA, Penning TM, Field J. 2002. Reactive oxygen species generated by PAH o-quinones cause change-in-function mutations in p53. Chem Res Toxicol 15:832–842.